[
    [
        {
            "time": "2020-10-22",
            "original_text": "阿斯利康新冠疫苗巴西试验出现1例患者死亡",
            "features": {
                "keywords": [
                    "阿斯利康",
                    "新冠疫苗",
                    "巴西试验",
                    "患者死亡"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "阿斯利康新冠疫苗巴西试验出现1例患者死亡",
                "Correlation": 7,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-10-22",
            "original_text": "贝达药业(300558.SZ)股东杭州贝昌减持296.68万股 减持时间已满 减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "杭州贝昌",
                    "减持",
                    "296.68万股"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)股东杭州贝昌减持296.68万股 减持时间已满 减持股份",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-22",
            "original_text": "贝达药业：盐酸埃克替尼片正式进入CDE优先审评程序",
            "features": {
                "keywords": [
                    "贝达药业",
                    "盐酸埃克替尼片",
                    "CDE优先审评"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业：盐酸埃克替尼片正式进入CDE优先审评程序",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-22",
            "original_text": "贝达药业(300558.SZ)：埃克替尼新适应症上市许可申请纳入优先审评程序",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "新适应症",
                    "优先审评"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：埃克替尼新适应症上市许可申请纳入优先审评程序",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-10-22",
            "original_text": "贝达药业：杭州贝昌减持计划时间届满，累计减持0.74%股份 拟减持股份",
            "features": {
                "keywords": [
                    "贝达药业",
                    "杭州贝昌",
                    "减持",
                    "0.74%股份"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：杭州贝昌减持计划时间届满，累计减持0.74%股份 拟减持股份",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        }
    ]
]